Roche Holding AG

RHHBY has broken down sharply below its EMA and horizontal support levels, signaling a shift into a medium-term bearish distribution phase. Short-term execution readiness is affirmed by high-volume red candles and failing retention at the 9/20 EMA band, while longer-term structural strength remains intact until price decisively breaches the 200-day SMA. The primary bias is bearish with immediate focus on resistance near the EMA zone and key support at the 200-day SMA.

• ↑10 Phase III molecules targeting high-value therapies bolster future revenue potential.
• ↑Q3 2025 group sales rose 7% YoY to CHF 25.6 bn; pharma +9%.
• ↓Negative growth outlook signals revenue expansion challenges ahead.